NasdaqGS - Nasdaq Real Time Price USD

AbCellera Biologics Inc. (ABCL)

2.5100

+0.0700

+(2.87%)

At close: June 9 at 4:00:01 PM EDT

2.5400

+0.03

+(1.20%)

After hours: June 9 at 7:59:18 PM EDT

AbCellera Biologics Inc. (ABCL): A Bull Case Theory

We came across a bullish thesis on AbCellera Biologics Inc. (ABCL) on Investment Ides by Antonio’s Substack. In this article, we will summarize the bulls’ thesis on ABCL. AbCellera Biologics Inc. (ABCL)’s share was trading at $2.14 as of 2nd June. ABCL’s trailing P/E was 19.92 according to Yahoo Finance. Abcellera is approaching a potential inflection point […]

Insider Monkey 15 hours ago

ABCL
+2.87%
ABCELLERA BIOLG (ABCL) Upgraded to Buy: Here's Why

ABCELLERA BIOLG (ABCL) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

Zacks 6 days ago

ABCL
+2.87%
AbCellera Biologics And 2 Other Promising Penny Stocks To Watch

The market has climbed by 2.0% over the past week, with every sector up, and in the last year, it has risen by 12%, showcasing a robust performance. For those interested in smaller or newer companies, penny stocks—despite their somewhat outdated name—can still offer intriguing opportunities for growth. With strong financial foundations, these stocks have the potential to outperform and provide stability; here we explore three such promising options that stand out as hidden gems in today's...

Simply Wall St. 6 days ago

CNDT

GDRX

ABCL
+2.87%
Why AbCellera Biologics Stock Raced Nearly 6% Higher Today

The company had some encouraging regulatory news to report. It concerned a dermatitis drug the biotech is currently developing. Investors were surely discovering drug discovery company AbCellera Biologics (NASDAQ: ABCL) as the trading week kicked off on Monday.

Motley Fool 7 days ago

ABCL
+2.87%
AbCellera Receives Authorization from Health Canada to Initiate a Phase 1 Clinical Trial of ABCL575

VANCOUVER, British Columbia, May 30, 2025--AbCellera Receives Authorization from Health Canada to Initiate a Phase 1 Clinical Trial of ABCL575

Business Wire 10 days ago

ABCL
+2.87%
AbCellera Biologics Inc. (ABCL): Analysts See 474% Upside Potential

We recently published an article titled 13 Best Multibagger Stocks to Invest in Now. AbCellera Biologics Inc. (NASDAQ:ABCL) was one of the stocks that was covered in that article. Wall Street analysts believe ABCL has a 474% upside potential over the next 12 months. AbCellera Biologics Inc. (NASDAQ:ABCL) is an AI-powered biotechnology company specializing in antibody […]

Insider Monkey 19 days ago

ABCL
+2.87%
Analyst Forecasts Just Became More Bearish On AbCellera Biologics Inc. (NASDAQ:ABCL)

The analysts covering AbCellera Biologics Inc. ( NASDAQ:ABCL ) delivered a dose of negativity to shareholders today, by...

Simply Wall St. 25 days ago

ABCL
+2.87%
AbCellera Receives Authorization from Health Canada to Initiate the Phase 1 Clinical Trial of ABCL635 for Vasomotor Symptoms Due to Menopause

VANCOUVER, British Columbia, May 14, 2025--AbCellera Receives Authorization from Health Canada to Initiate the Phase 1 Clinical Trial of ABCL635 for Vasomotor Symptoms Due to Menopause

Business Wire 26 days ago

ABCL
+2.87%
AbCellera’s Microfluidic Cell Culture Patent Affirmed Valid by the U.S. Court of Appeals for the Federal Circuit

VANCOUVER, British Columbia, May 12, 2025--AbCellera’s Microfluidic Cell Culture Patent Affirmed Valid by the U.S. Court of Appeals for the Federal Circuit

Business Wire 28 days ago

ABCL
+2.87%
AbCellera Biologics First Quarter 2025 Earnings: Revenues Disappoint

AbCellera Biologics ( NASDAQ:ABCL ) First Quarter 2025 Results Key Financial Results Revenue: US$4.24m (down 57% from...

Simply Wall St. 30 days ago

ABCL
+2.87%
AbCellera Presents Positive Preclinical Data on ABCL575 at the 2025 SID Annual Meeting

VANCOUVER, British Columbia, May 09, 2025--AbCellera Presents Positive Preclinical Data on ABCL575 at the SID Annual Meeting 2025

Business Wire last month

ABCL
+2.87%
AbCellera Biologics Inc (ABCL) Q1 2025 Earnings Call Highlights: Navigating Challenges with ...

Despite a revenue dip, AbCellera Biologics Inc (ABCL) focuses on advancing clinical programs and strengthening its liquidity position.

GuruFocus.com last month

ABCL
+2.87%
AbCellera Biologics Inc. (ABCL) Reports Q1 Loss, Misses Revenue Estimates

AbCellera Biologics (ABCL) delivered earnings and revenue surprises of 11.76% and 49.82%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?

Zacks last month

ABCL
+2.87%
AbCellera Reports Q1 2025 Business Results

VANCOUVER, British Columbia, May 08, 2025--AbCellera Reports Q1 2025 Business Results

Business Wire last month

ABCL
+2.87%
AbCellera Presents Data Showing Preclinical Efficacy of PSMA x CD3 T-Cell Engagers at AACR 2025

VANCOUVER, British Columbia, April 29, 2025--AbCellera presents data showing preclinical efficacy of PSMA x CD3 T-Cell Engagers at AACR 2025.

Business Wire last month

ABCL
+2.87%
3 Promising Penny Stocks With Market Caps Up To $800M

The U.S. stock market has recently experienced a surge, driven by optimism surrounding reduced tariffs on China and a rally in the technology sector. For investors seeking opportunities beyond established giants, penny stocks—typically smaller or newer companies—present intriguing possibilities for growth and diversification. While the term "penny stocks" may seem outdated, these investments continue to offer potential when supported by strong financials and fundamentals. In this article, we...

Simply Wall St. last month

CLNE

ABCL
+2.87%

BRSP
Is AbCellera Biologics Inc. (ABCL) the Best Canadian Penny Stock to Invest in Now?

We recently published a list of 13 Best Canadian Penny Stocks to Invest in Now In this article, we are going to take a look at where AbCellera Biologics Inc. (NASDAQ:ABCL) stands against other best Canadian penny stocks to invest in now. We define penny stocks as shares trading under $5.00, which usually fall into […]

Insider Monkey last month

ABCL
+2.87%
AbCellera to Participate at Upcoming Investor Conferences in May and June

VANCOUVER, British Columbia, April 08, 2025--AbCellera to Participate at Upcoming Investor Conferences in May and June

Business Wire 2 months ago

ABCL
+2.87%
AbCellera to Report First Quarter 2025 Financial Results on May 8, 2025

VANCOUVER, British Columbia, April 03, 2025--AbCellera to Report First Quarter 2025 Financial Results on May 8, 2025

Business Wire 2 months ago

ABCL
+2.87%

Performance Overview

Return	ABCL	S&P 500 (^GSPC)
YTD	-14.33%	+2.11%
1-Year	-30.66%	+12.32%
3-Year	-70.08%	+49.48%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

AbCellera Biologics Inc. (ABCL)

AbCellera Biologics Inc. (ABCL): A Bull Case Theory

ABCELLERA BIOLG (ABCL) Upgraded to Buy: Here's Why

AbCellera Biologics And 2 Other Promising Penny Stocks To Watch

Why AbCellera Biologics Stock Raced Nearly 6% Higher Today

AbCellera Receives Authorization from Health Canada to Initiate a Phase 1 Clinical Trial of ABCL575

AbCellera Biologics Inc. (ABCL): Analysts See 474% Upside Potential

Analyst Forecasts Just Became More Bearish On AbCellera Biologics Inc. (NASDAQ:ABCL)

AbCellera Receives Authorization from Health Canada to Initiate the Phase 1 Clinical Trial of ABCL635 for Vasomotor Symptoms Due to Menopause

AbCellera’s Microfluidic Cell Culture Patent Affirmed Valid by the U.S. Court of Appeals for the Federal Circuit

AbCellera Biologics First Quarter 2025 Earnings: Revenues Disappoint

AbCellera Presents Positive Preclinical Data on ABCL575 at the 2025 SID Annual Meeting

AbCellera Biologics Inc (ABCL) Q1 2025 Earnings Call Highlights: Navigating Challenges with ...

AbCellera Biologics Inc. (ABCL) Reports Q1 Loss, Misses Revenue Estimates

AbCellera Reports Q1 2025 Business Results

AbCellera Presents Data Showing Preclinical Efficacy of PSMA x CD3 T-Cell Engagers at AACR 2025

3 Promising Penny Stocks With Market Caps Up To $800M

Is AbCellera Biologics Inc. (ABCL) the Best Canadian Penny Stock to Invest in Now?

AbCellera to Participate at Upcoming Investor Conferences in May and June

AbCellera to Report First Quarter 2025 Financial Results on May 8, 2025

Performance Overview